Compare · ELV vs NTRA
ELV vs NTRA
Side-by-side comparison of Elevance Health Inc. (ELV) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $84.37B, about 2.5x NTRA ($33.14B).
- Over the past year, ELV is up 4.4% and NTRA is up 35.7% - NTRA leads by 31.4 points.
- NTRA has been more active in the news (18 items in the past 4 weeks vs 7 for ELV).
- NTRA has more recent analyst coverage (25 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Natera Inc.
- Price
- $388.60-0.68%
- $231.43+2.17%
- Market cap
- $84.37B
- $33.14B
- 1M return
- -3.47%
- +18.03%
- 1Y return
- +4.36%
- +35.71%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 7
- 18
- Recent ratings
- 23
- 25
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest ELV
- SEC Form 11-K filed by Elevance Health Inc.
- SEC Form 11-K filed by Elevance Health Inc.
- Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide
- CAO & Controller Penczek Ronald W sold $148,766 worth of shares (369 units at $403.16), decreasing direct ownership by 9% to 3,740 units (SEC Form 4)
- Elevance Health Makes Chronic Care Easier to Navigate With Connected, Personalized Support
- Director Dixon Robert L Jr sold $60,667 worth of shares (151 units at $401.77), decreasing direct ownership by 1% to 10,734 units (SEC Form 4)
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
Latest NTRA
- Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
- Director Chapman Rowan E sold $642,536 worth of shares (2,964 units at $216.78) as part of a pre-agreed trading plan, decreasing direct ownership by 49% to 3,124 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $665,087 worth of shares (3,150 units at $211.14) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 249,352 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $21,447,308 worth of shares (100,000 units at $214.47) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 2,277,843 units (SEC Form 4)
- Amendment: Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- RBC Capital Mkts resumed coverage on Natera with a new price target
- Director Marcus Gail Boxer sold $2,389,328 worth of shares (11,000 units at $217.21) and exercised 11,000 shares at a strike of $22.83 (SEC Form 4)
- SEC Form 3 filed by new insider Lynch Thomas J. Jr.
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)